AMENDMENT TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-31. (canceled)

32. (currently amended) A method for treating or managing a ~~disease associated with an elevated~~ metalloproteinase (MMP) or calpain related disease or disorder in a mammal ~~as compared to the control level of metalloproteinase (MMP) or calpain found in a normal mammal~~ , the disease or disorder being selected from the group consisting of cancer metastatis and glioma comprising administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of a compound of the Formula (I):

(I)



wherein

R is saturated or unsaturated alkyl, cycloalkyl, arylalkyl or cycloalkyl-alkyl radical having from 1 to 28 carbon atoms which may be interrupted by any combination of 1-6 oxygen and/or nitrogen atoms, provided that no two oxygen atoms or an oxygen and a nitrogen atom are directly connected to each other; and

M denotes a hydrogen or a physiologically acceptable cation.

33. (previously presented) The method according to claim 32, wherein said method further comprises treating the mammal with additional therapeutic treatment.

34. (previously presented) The method according to claim 32, wherein said mammal is a human.

35. (currently amended) The method according to claim 32, wherein said MMP related disease or disorder is cancer metastasis~~disease associated with an elevated metalloproteinase (MMP) or calpain is selected from the group consisting of cancer, trauma, inflammatory conditions and diseases, atherosclerosis, thrombotic disorders, arthritis, hemorrhage, rheumatic diseases, autoimmune diseases, and migraine~~.

36 to 37. (cancelled)

38. (currently amended) The method according to claim 32, wherein R in the compound of Formula (I) is a phenylalkyl ~~phenylakyl~~, and alky interrupted by zero to three oxygen atoms, or a monoalkyl ether of mono-, di-, or tri-ethylene glycol.

39. (previously presented) The method according to claim 32, wherein R in the compound of Formula (I) is selected from the group consisting of: C_8H_{17}, $C_8H_{17}OCH_2CH_2$, $C_{18}H_{37}$, $C_{18}H_{37}OCH_2CH_2$, benzyl-$CH_2OCH_2CH_2$, $C_{12}H_{25}OCH_2CH_2$, $C_{12}H_{25}(OCH_2CH_2)_2$ and $C_{12}H_{25}(OCH_2CH_2)_3$.

40. (currently amended) The method according to claim 32, wherein the metalloproteinase is MMP-9.

41 to 44. (cancelled)

45. (previously presented) The method according to claim 33, wherein said additional treatment is selected from the group consisting of chemotherapy, irradiation therapy, immunotherapy, genetic therapy and surgery.

46. (currently amended) The method according to claim 32, wherein said compound of Formula (I) is selected from the group consisting of:

1,2-bis(2-aminophenoxy)ethane, N,N′-di(2-octoxyethyl acetate),N, N′-diacetic acid;

1,2-bis(2-aminophenoxy)ethane, N, N′-di(2-octodecyloxyethyl acetate),N, N′-diacetic acid;

1,2-bis(2-aminophenoxy)ethane, N, N′-di(2-benzyloxyethyl acetate),N, N′-acetic acid;

1,2-bis(2-aminophenoxy)ethane, N, N′-di(2-dodecyloxyethyl acetate)~~-di(2-dodecyloctoxyethyl acetate)~~,N, N′-diacetic acid;

1,2-bis(2-aminophenoxy)ethane, N, N′-di[2-(2-dodecyloxyethoxy)-ethyl acetate],N, N′-diacetic acid; and

1,2-bis(2-aminophenoxy)ethane, N, N′-di{2[2-(2-dodecyloxyethoxy)ethoxy]-ethyl acetate},N, N′-diacetic acid.

47. (new) The method according to claim 32, wherein said MMP related disease or disorder is glioma.